

<b>All blanks in the datasets represent information missing unless otherwise specified in data dictionary.</b>		
<b>No subsequent data was collected for patients where exclude = 1. Fields are left blank for these patients.</b>		
<b>Minor discrepancies exist between the dataset and the publication because of minor errors in the publication. These are noted in an erratum submitted to the Journal of Clinical Oncology on April 13, 2017</b>		
<b>Variable</b>	<b>Label</b>	<b>Description</b>
USI	USI ID	
Eligible	Eligibility of the Study	0 = NO; 1 = Yes
exclude	Exclude/Include in study	0 = Include; 1 = Exclude
exclude_reason	Reason of Exclusion	Blank = Not applicable
Group	Group	0 = Doxorubicin Alone; 1 = Doxorubicin + Dexrazoxane
disease	Disease type	T-ALL; NHL
age	Age at diagnosis (years)	
SEX	Gender	1 = Male; 2 = Female
race	Race	1 = White; 2 = Non-White
wbc	Number of white blood cells (x10 <sup>3</sup> /MicroLiter)	
fu_yrs	Follow-up time in years	
M_STAGE	L-NHL stage	3 = Stage III; 4 = Stage IV
cns_c	CNS Status	0 = CNS Negative (CNS0/CNS1); 1 = CNS Positive (CNS2/3/bloody tap)
tox_infection	Grade 3 or 4 infection toxicity	0 = No; 1 = Yes
tox_heme	Grade 3 or 4 hematologic effects toxicity	0 = No; 1 = Yes
tox_mucositis	Grade 3 or 4 mucositis toxicity	0 = No; 1 = Yes
tox_cns	Grade 3 or 4 CNS effects toxicity	0 = No; 1 = Yes
cardiac_tox	Cardiac Toxicity	No; Arrhythmia; ECHO FS
echo_count	Number of echocardiograms	
echo_yes	Patients with echocardiograms at least on time point.	0 = No; 1 = Yes
echo1a	With echocardiograms at baseline	0 = No; 1 = Yes
echo2a	With echocardiograms at week 34	0 = No; 1 = Yes
echo3a	With echocardiograms at 3-year	0 = No; 1 = Yes
echo_late_a	With echocardiograms between 3.5 - 6.5 years	0 = No; 1 = Yes
ntpn	Number of troponin measures	
troponin_bln	baseline troponin	0 = No; 1 = Yes
high_tpn_base	Baseline troponin > 0.01 ng/mL?	0 = No; 1 = Yes
high_tpn_post	Troponin > 0.01 ng/mL after treatment started?	0 = No; 1 = Yes
maxtpn	highest level of troponin	
troponin_pair	Troponin concentrations availability at both baseline and during treatment	0 = No; 1 = Yes
site_of_relapse	Relapse site	1 = Marrow ± Other; 2 = CNS ± Other; 3 = Other; Blank = Unknown/Not Applicable

first_event	First event	1 = Induction failure; 2 = Induction death; 3 = Relapse; 4 = SMN; 5 = Remission Death; Blank = No event
EFS_time	Event-free survival time in days	Blank = Not applicable
EFS_status	EFS status	0 = Censored; 1 = Event ; Blank = Not applicable
OS_time	Overall survival time in days	Blank= Not applicable
OS_status	Overall survival status	0 = Censored; 1 = Death; Blank = Not applicable
SMN	SMN status	0 = Censored; 1 = SMN; 2 = Other Event; Blank = Not applicable
SMN_time	Time to SMN in days	Blank = Not applicable
tox_death	Death type	0 = Remission death off therapy; 1 = Toxic death; Blank = Not applicable
fractional_shortening_z_score1	Z score for LV fractional shortening at baseline	
fractional_shortening_z_score2	Z score for LV fractional shortening at end of DOX treatment	
fractional_shortening_z_score3	Z score for LV fractional shortening at 3-year	
fractional_shortening_z_late	Z score for LV fractional shortening measured 3.5 to 6.4 years after diagnosis	
frac_short_base_endtx	Z score change for LV fractional shortening between baseline and end of DOX treatment	
frac_short_base_3yr	Z score change for LV fractional shortening between baseline and 3-year	
end_diastolic_dim_z_score1	Z-score for LV end-diastolic dimension at baseline	
end_diastolic_dim_z_score2	Z-score for LV end-diastolic dimension at end of DOX treatment	
end_diastolic_dim_z_score3	Z-score for LV end-diastolic dimension at 3-year	
end_diastolic_dim_z_late	Z-score for LV end-diastolic dimension measured 3.5 to 6.4 years after diagnosis	
end_dia_dim_base_endtx	Z-score change for LV end-diastolic dimension between baseline and end of treatment	

end_dia_dim_base_3yr	Z-score change for LV end-diastolic dimension between baseline and 3-year	
left_ventricular_mass_z_score1	Z score for LV mass at baseline	
left_ventricular_mass_z_score2	Z score for LV mass at end of DOX treatment	
left_ventricular_mass_z_score3	Z score for LV mass at 3-year	
left_ventricular_mass_z_late	Z score for LV mass measured 3.5 to 6.4 years after diagnosis	
lv_mass_base_endtx	Z score change for LV mass between baseline and end of treatment	
lv_mass_base_3yr	Z score change for LV mass between baseline and 3-year since DOX treatment	
wall_thickness_z_score1	Z score for wall thickness at baseline	
wall_thickness_z_score2	Z score for wall thickness at end of DOX treatment	
wall_thickness_z_score3	Z score for wall thickness at 3-year since DOX treatment	
wall_thickness_z_late	Z score for wall thickness measured 3.5 to 6.4 years after diagnosis	
wall_thick_base_endtx	Z score change for wall thickness between baseline and end of DOX treatment	
wall_thick_base_3yr	Z score change for wall thickness between baseline and 3-year	
thick_dim_ratio_z_score1	Z-score for thickness-to-end diastolic dimension ratio at baseline	
thick_dim_ratio_z_score2	Z-score for thickness-to-end diastolic dimension ratio at end of DOX treatment	
thick_dim_ratio_z_score3	Z-score for thickness-to-end diastolic dimension ratio at 3-year	
thick_dim_ratio_z_late	Z-score for thickness-to-end diastolic dimension ratio measured 3.5 to 6.4 years after diagnosis	
thick_dim_ratio_base_endtx	Z-score change for thickness-to-end diastolic dimension ratio between baseline and end of treatment	

thick_dim_ratio_base_3yr	Z-score change for thickness-to-end diastolic dimension ratio between baseline and 3-year	
--------------------------	---	--